Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone

CONCLUSION: In this cohort, KRd was not associated with an increase in VTE risk compared to VRd, contrary to prior literature.PMID:37543510 | DOI:10.1016/j.clml.2023.07.009
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research